The Foundation for Addie’s Research initiatied its partnership with Oncoheroes Biosciences in June 2022 providing crucial support for Oncoheroes’ initial strides towards advancing clinical development for its lead compound, Volasertib.
Today, the Foundation for Addie’s Research renews its commitment to Oncoheroes’ mission of discovering effective therapies for pediatric cancer patients by providing additional support to initiate a clinical trial to evaluate Volasertib’s effectiveness in treating five aggressive pediatric cancers. This international trial, organized in partnership with Hopp Children’s Cancer Center Heidelberg (KiTZ), will take place in different sites across Europe, the United Kingdom and Australia, and represents a new beacon of hope for children and adolescents who have exhausted their treatment options.
Christina Stiverson, President of the Foundation for Addie’s Research, conveyed her enthusiasm about this pivotal development, stating, 'We are extremely excited to see the Volasertib trial move forward from bench science to the bedside. After years of supporting pre-clinical research on Volasertib, we are grateful for our partnership with Oncoheroes to make this treatment available for patients with rare pediatric cancers.'
The Foundation for Addie’s Research stems from the brave journey of Adelaide, “Addie”, a courageous childhood cancer who battled Hepatoblastoma and saddly passed away in 2016 at the age of three. This foundation is focused on pre-clinical research and innovative trials aiming to expand treatment options for children facing circumstances similar to Addie’s. In addition, Foundation for Addie’s Research created the Hepatoblastoma Resource Network, a comprehensive resource hub designated to unite and support families within the fragmented rare cancer community.
